Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBBP9 | O75884 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836245 | 1.00 | RBBP9 (0.51) | RBBP9CYP1A2CYP2D6CYP2C19CASP3 | |
| SCHEMBL21836279 | 0.72 | KDM4E (0.58) | KMT2AMAOAMAOBALDH1A1MAPT | |
| SCHEMBL21836280 | 0.72 | KDM4E (0.58) | KMT2AMAOAMAOBALDH1A1MAPT | |
| SCHEMBL21836228 | 0.72 | HCAR2 (0.42) | CYP1A2CYP2C19ALDH1A1MAPTMITF | |
| SCHEMBL1254922 | 0.72 | ALDH1A1 (0.59) | RBBP9CYP1A2CYP2D6CYP2C19CASP3 | |
| SCHEMBL21836209 | 0.71 | FFAR2 (0.39) | RBBP9CYP1A2CYP2C19KMT2AALDH1A1 | |
| SCHEMBL2948824 | 0.70 | — | — | |
| SCHEMBL13237108 | 0.70 | — | — | |
| SCHEMBL2948821 | 0.70 | — | — | |
| SCHEMBL21836260 | 0.70 | LMNA (0.44) | CYP1A2CYP2D6KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| CN-111032047-A | Process for producing optically active compound | 千年制药公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988469-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | RBBP9 1254/4885CYP1A2 1113/4885CYP2D6 484/4885 |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | RBBP9 1254/4885CYP1A2 1113/4885CYP2D6 484/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | RBBP9 1254/4885CYP1A2 1113/4885CYP2D6 484/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | RBBP9 1254/4885CYP1A2 1113/4885CYP2D6 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.